Dorota Tomalik‐Scharte

Should We Use <i>N</i> -Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?

Martina Kinzig‐Schippers, Dorota Tomalik‐Scharte, Alexander Jetter et al. · Antimicrobial Agents and Chemotherapy · 2005 · 197 citations · Full text

Molecular Pharmacology, High-activity Nat2 Allele, Pharmacological Study +12

Toxicokinetics of Acrylamide in Humans after Ingestion of a Defined Dose in a Test Meal to Improve Risk Assessment for Acrylamide Carcinogenicity

Uwe Fuhr, Melanie I. Boettcher, Martina Kinzig‐Schippers et al. · Cancer Epidemiology Biomarkers & Prevention · 2006 · 179 citations

Defined Dose, Acrylamide Carcinogenicity, Dietary Exposure +14

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

Julia Kirchheiner, Stefanie M. Thomas, Steffen Bauer et al. · Clinical Pharmacology & Therapeutics · 2006 · 124 citations

Absorption, Pharmacokinetics, and Safety of Triclosan after Dermal Administration

Christian Queckenberg, Jürgen Meins, Bertil Wachall et al. · Antimicrobial Agents and Chemotherapy · 2009 · 97 citations · Full text

Hydrophobic Creams, Dermal Application, Medicine +12

Dermal absorption of permethrin following topical administration

Dorota Tomalik‐Scharte, A. Lazar, Jean‐François Le Meins et al. · European Journal of Clinical Pharmacology · 2005 · 83 citations

Dermal Absorption, Medicine, Topical Drug +4